story of the week
Final Overall Survival Analysis Supports First-Line Sunitinib Followed by Everolimus in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
Final Overall Survival Analysis for the Phase II RECORD-3 Study of First-Line Everolimus Followed by Sunitinib Versus First-Line Sunitinib Followed by Everolimus in Metastatic RCC
Ann. Oncol 2017 Feb 21;[EPub Ahead of Print], JJ Knox, CH Barrios, TM Kim, T Cosgriff, V Srimuninnimit, K Pittman, R Sabbatini, SY Rha, TW Flaig, RD Page, JT Beck, F Cheung, S Yadav, P Patel, L Geoffrois, J Niolat, N Berkowitz, M Marker, D Chen, RJ MotzerRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.